Loading organizations...
Expedition Therapeutics is a biotechnology company based in San Francisco, California, focused on developing novel therapies for serious inflammatory and respiratory diseases, particularly chronic obstructive pulmonary disease. The firm advances its clinical pipeline through strategic asset acquisition, recently securing global development and commercialization rights outside of China to a next-generation DPP1 inhibitor from Fosun. To accelerate these clinical development programs, the enterprise successfully raised $165 million in an oversubscribed Series A venture capital financing round in October 2025. This significant equity funding was supported by a syndicate of prominent life sciences investors, including Forbion, Novo Holdings, and BVF Partners. The organization's strategic direction is guided by a leadership team that includes Board Chairman Andrew Cheng, who previously served as the Chief Medical Officer of Gilead. Expedition Therapeutics was founded in 2024 by Chief Executive Officer Yi Larson.
Expedition Therapeutics has raised $170.0M across 1 funding round.
Expedition Therapeutics has raised $170.0M in total across 1 funding round.
Expedition Therapeutics has raised $170.0M in total across 1 funding round.
Expedition Therapeutics's investors include BoxOne Ventures, Sofinnova Investments.
Expedition Therapeutics has raised $170.0M across 1 funding round. Most recently, it raised $170.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $170M Series A | — | BoxOne Ventures, Sofinnova Investments | Announced |
Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases, with its lead candidate EXPD-101, a next-generation oral DPP1 inhibitor targeting neutrophilic inflammation in COPD and other neutrophil-driven conditions like bronchiectasis and neutrophilic asthma.[1][4] The company serves patients lacking disease-controlling treatments—nearly 70% of COPD cases—and aims to transform care by blocking neutrophil serine proteases (NSPs) that drive airway damage without depleting neutrophils or compromising immune function.[1][4] EXPD-101 demonstrated safety, target engagement, and once-daily pharmacokinetics in Phase 1 trials and is advancing to global Phase 2 in COPD, bolstered by a $165 million oversubscribed Series A in 2025 co-led by Sofinnova Investments and Novo Holdings.[4][5]
Expedition Therapeutics was founded around 2025 and is based in San Francisco, led by Yi Larson as Founder and CEO, alongside a seasoned team of biotech executives, scientists, and clinicians experienced in respiratory therapeutics, drug development, and commercialization.[1][2][4] The company emerged from strategic in-licensing, acquiring exclusive worldwide rights (excluding mainland China, Hong Kong, and Macau) to EXPD-101 from Fosun Pharma in August 2025, building on Fosun's ongoing Phase 2 bronchiectasis study in China.[4][5] Early traction includes Phase 1 success and substantial funding from investors like Venrock Healthcare Capital Partners, BVF Partners, Forbion, Dawn Biopharma (KKR), Adage, Balyasny, Logos Capital, and Sanofi Ventures, positioning it for rapid global advancement.[4]
(Note: One profile lists a focus on cancer therapies, but primary sources confirm respiratory and inflammatory diseases.[2])
Expedition rides the wave of precision respiratory medicine, targeting unmet needs in COPD—affecting millions with no disease-modifying options—amid rising demand for neutrophil-focused therapies in inflammatory diseases.[1][4] Timing aligns with China's biotech boom, enabling cost-effective in-licensing of advanced assets like EXPD-101, while global Phase 2 trials capitalize on post-pandemic focus on lung health.[5] Market forces favor it: aging populations drive COPD prevalence, and investor enthusiasm (e.g., oversubscribed Series A) reflects biotech's shift toward high-impact, mechanism-driven drugs over broad immunosuppressants.[4] Expedition influences the ecosystem by bridging U.S. development with Asian innovation, potentially setting standards for cross-border biotech partnerships.[4][5]
Expedition is primed for Phase 2 readout in COPD and bronchiectasis, with expansion into additional indications and potential milestones triggering up to $645M in Fosun payments.[4][5] Trends like AI-enhanced drug design and covalent chemistry in adjacent biotechs could accelerate its pipeline, though it differentiates via validated clinical data.[3] Its influence may grow as a leader in neutrophilic inflammation, delivering first/best-in-class therapies that redefine COPD standards—transforming patient care from symptom management to disease control, as promised from inception.[1]
